v3.19.3.a.u2

Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2019 | Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | $ 60,209 |
Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 48,036 |
Balance without adoption of ASC 606 |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 94,978 |
Balance without adoption of ASC 606 | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 82,805 | $ 122,512
Merck | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 36,608 |
Merck | Balance without adoption of ASC 606 | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 38,977 | 66,082
AstraZeneca | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 5,233 |
AstraZeneca | Balance without adoption of ASC 606 | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 37,235 | 45,993
Vertex | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | 6,195 |
Vertex | Balance without adoption of ASC 606 | Collaboration Revenue by Strategic Collaborator |  |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] |  |
Total collaboration revenue | $ 6,593 | $ 10,437

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_VertexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |